Not Yet RecruitingPhase 4

Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

China200 participantsStarted 2025-04-01

Plain-language summary

Heart failure (HF) is a severe cardiovascular disease with extremely high morbidity and mortality rates worldwide, and ischemic cardiomyopathy is an important cause of heart failure. Vericiguat is a soluble guanylate cyclase stimulator which has been verified to improve the cardiovascular outcomes in heart failure patients. The VICTORIA trial excluded patients with acute coronary syndrome in 3 months prior to the study start, so it is still unclear about the efficacy and safety of vericiguat in heart failure after acute myocardial infarction. So we conducted this multi-center, prospective, cohort study to estimate the efficacy and safety of vericiguat in HF patients after acute myocardial infarction.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years old * Undertaking revascularization for criminal coronary artery during hospitalization * Acute heart failure occurs within 14 days in hospital after STEMI or NSTEMI, meeting all of the following criteria: typical symptoms or signs of heart failure; Treatment with oral or intravenous diuretics is required; LVEF measured by echocardiography is ≤ 45%; Elevated levels of NT proBNP in patients with sinus rhythm ≥ 1000pg/ml and atrial fibrillation/flutter ≥ 1600pg/ml * eGFR ≥ 15 ml/min/1.73m2 * Informed consent has to be given in written form Exclusion Criteria: * Plan to undergo staged revascularization or if the criminal coronary artery has not been successfully opened * Severe and uncontrolled lung diseases, such as newly developed pulmonary embolism, primary pulmonary hypertension, acute exacerbation of COPD, etc * Severe liver and kidney dysfunction, Child Pugh grade C or eGFR \< 15ml/min/1.73m2 * Allergies to ACEI, ARB, ARNI, beta blockers, SGLT2i, MRA, Vericiguat, and other medications * Symptomatic hypotension or systolic blood pressure less than 90mmHg after discontinuing intravenous medication * Women in the perinatal period or those planning to conceive * Patients planning to undergo elective surgical treatment or tumor chemotherapy * Diagnosed as Takotsubo cardiomyopathy or nonobstructive acute myocardial infarction (MINOCA) * Previous diagnosis of cardiomyopathy, including but not limited to dilated cardiomyopathy, hypertrophic …

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial is testing vericiguat started early after a heart attack combined with acute heart failure — given that I've just had a heart attack, is the timing of when vericiguat might be introduced something we should be actively discussing for my situation?
2The trial is measuring NT-proBNP levels as its main outcome — can you explain what that marker tells us about how my heart is recovering, and whether my current NT-proBNP results suggest this kind of treatment approach might be relevant for me?
3Since this is a Phase 4 trial, vericiguat is already an approved medication — does that mean there's more known about its safety compared to earlier-phase trials, and how does that affect the risk-benefit conversation for someone in my position?
4The trial isn't recruiting yet — if I might be interested in something like this down the road, what standard treatments should I be focused on right now, and could pursuing those first affect whether I'd even be eligible later?
5Heart failure after a heart attack can be a fast-moving situation — how would participating in a trial like this fit around my current recovery plan, and are there logistical demands like extra clinic visits or blood tests that I should factor into my decision?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Serum NT-proBNP Level

Timeframe: Up to 24 weeks

Trial details

NCT IDNCT06812546

SponsorDongying Zhang

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-30

Contact for this trial

Dongying Zhang, Professor

86-13608398395 zhangdongying@cqu.edu.cn

View on ClinicalTrials.gov More Heart Failure trials